Ret Proto-Oncogene anticorps (AA 896-1063)

N° du produit ABIN1724684

Détail du produit anti-Ret Proto-Oncogene anticorps

Antigène: Ret Proto-Oncogene (RET)

Épitope: AA 896-1063

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp Ret Proto-Oncogene est non-conjugé

Application: Western Blotting (WB), ELISA

Purification: purified

Immunogène: Purified recombinant fragment of RET (aa896-1063) expressed in E. coli.

Clone: 6E4C4

Isotype: IgG1

Information d'application

Indications d'application: ELISA: 1:10000, WB: 1:500 - 1:2000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C/-20 °C

Stockage commentaire: 4°C, -20°C for long term storage

Références pour anticorps anti-Ret Proto-Oncogene (ABIN1724684)

Young, Anderson, Anderson: "Guidance cues involved in the development of the peripheral autonomic nervous system." dans: Autonomic neuroscience : basic & clinical, Vol. 112, Issue 1-2, pp. 1-14, (2004) (PubMed).

Myers, Mulligan: "The RET receptor is linked to stress response pathways." dans: Cancer research, Vol. 64, Issue 13, pp. 4453-63, (2004) (PubMed).

Détails sur Ret Proto-Oncogene

Antigène: Ret Proto-Oncogene (RET)

Autre désignation: RET (RET Produits)

Synonymes: anticorps c-ret, anticorps cret, anticorps etID315074.13, anticorps ret1, anticorps wu:fd13h01, anticorps X-ret, anticorps ret-A, anticorps xret, anticorps RET, anticorps MTC1, anticorps CDHF12, anticorps CDHR16, anticorps HSCR1, anticorps MEN2A, anticorps MEN2B, anticorps PTC, anticorps RET-ELE1, anticorps RET51, anticorps RET9, anticorps c-Ret, anticorps ret proto-oncogene receptor tyrosine kinase, anticorps ret proto-oncogene S homeolog, anticorps ret proto-oncogene, anticorps ret, anticorps ret.S, anticorps RET, anticorps Ret

Sujet:

Description: RET (ret proto-oncogene) is a member of the cadherin superfamily and a receptor tyrosine kinase, which are cell-surface molecules that transduce signals for cell growth and differentiation. It can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Ligands that bind the Ret receptor include the glial cell line-derived neurotropic factor (GDNF) and its congeners neurturin, persephin and artemin. Alterations in the corresponding Ret gene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma and a congenital developmental disorder known as Hirschsprung disease. The Tyr905 residue located in the Ret kinase domain plays a crucial role in Ret catalytic and biological activity. Substitution of Phe for Tyr905 dramatically inhibits Ret autophosphorylation activity.

Aliases: RET

ID gène: 5979

HGNC: 5979

Pathways: Signalisation RTK, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation